MSD has fleshed out its cardiovascular disease pipeline by licensing an oral Lp(a) inhibitor from China's Jiangsu Hengrui Pharma for $200 million upfront. The deal gives MSD exclusive rights to the ...
Kelun-Biotech has become the second drugmaker to bring a TROP2-directed antibody-drug conjugate to regulatory approval, getting a green light in China for sacituzumab tirumotecan (sac-TMT). The ...
Narrator: Ooooh, new magnet? Go on then, let’s see it in action. Ooooh. Haha, whoops! Does that mean things will be attracted to you now? Uh oh! Those forks look pointy! Hey, why aren’t those metal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback